Furthermore, the enhanced tumor-suppressing effects observed when APC11 peptides were combined with anti-PD1 antibodies highlight a promising therapeutic strategy, providing a strong rationale for further development of anti-tumor agents and clinical trials for CRC patients. This evidence concerns the gene PDCD1 and neoplasm.